After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Moderna Inc is $21.03B. A total of 4.27 million shares were traded on the day, compared to an average of 5.11M shares.
In the most recent transaction, Mock James M sold 715 shares of MRNA for 60.12 per share on Oct 07 ’24. After the transaction, the Chief Financial Officer now owns 9,505 company shares. In a previous transaction on Sep 09 ’24, Klinger Shannon Thyme sold 551 shares at 73.57 per share. MRNA shares that Chief Legal Officer owns now total 18,154.
Among the insiders who bought shares, Klinger Shannon Thyme acquired of 551 shares on Sep 09 ’24 at a per-share price of $73.57. In another insider transaction, Klinger Shannon Thyme sold 114 shares at $76.99 per share on Sep 03 ’24. Company shares held by the Chief Legal Officer now total 17,566.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, MRNA has a high of $170.47 and a low of $52.26.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. MRNA’s latest balance sheet shows that the firm has $10.73B in Cash & Short Term Investments as of fiscal 2021. There were $916.00M in debt and $9.13B in liabilities at the time. Its Book Value Per Share was $30.50, while its Total Shareholder’s Equity was $14.14B.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MRNA is Buy with a score of 3.35.
